Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Italy
  4. Borsa Italiana
  5. Recordati
  6. News
  7. Summary
    REC   IT0003828271

RECORDATI

(REC)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

2021 First nine months results

10/28/2021 | 09:33am EST

2021 First Nine Months Results

Milano, 28th October 2021

First nine months 2021 highlights

  • Q3 results continued to reflect the positive trends already seen in Q2, with rebound of revenue across SPC, strong contribution from Eligard(1) (all key markets now selling directly) and continued strong growth of Rare Diseases
  • YTD Q3 net revenue of €1,156.2 million was +5.7% vs PY or +8.6% at CER; excluding Eligard® revenue of €59.4 million, growth in CER would be +3.2%, with good revenue momentum in recent months more than off-setting the full year impact of 2020 LOEs and impact of Covid-19 restrictions particularly on flu medicines in 1H
  • Financial results are in line with expectations, with operating results reflecting planned increased investment behind Endo and Eligard® and return to higher level of activity in the field. Results also reflect higher financial charges (due to FX volatility) and non-recurring tax benefits of €26.2 million recognized in Q2:
    • EBITDA(2) €447.9 million or 38.7% of sales, +2.1%
    • Net Income €296.4 million or 25.6% of sales, +8.1%
    • Adjusted Net Income(3) €313.4 million or 27.1% of sales, -1.3%
    • Free cash flow(4) €352.9 million, an increase of € 69.6 million vs same period 2020
  • Continued focus on ESG agenda results in MSCI rating improvement and inclusion in Euronext MIB ESG index
  • Board approved interim 2021 dividend of € 0.53 per share, consistent with our dividend policy
  • Approved a share buy-back program for a maximum of 1 million shares to service the stock option plans
    1. Acquired under license from Tolmar International Ltd. in January 2021
    2. Net income before income taxes, financial income and expenses, depreciation, amortization and write-downs of property, plant and equipment, intangible assets and goodwill, and non-recurring items

2 (3) Net income excluding the amortization and write-downs of intangible assets (except software) and goodwill, and non-recurring items, net of tax effects

(4) Operating cash flow excluding financing items, milestones, dividends, purchases of treasury shares net of proceeds from exercise of stock options

Eligard® transition ahead of plan, with positive early signals from active promotion

Revenue of €59.4 million* is ahead of expectations due to earlier switch to direct sales and Recordati promotion in several markets

Recordati is MA Holder in all Mutual Recognition Procedure markets, with around 30 Marketing Authorisation Transfers completed before the end of September

Eligard® is being promoted directly by our affiliates in 24 countries and indirectly by our partners in 6 additional countries with positive feedback from HCPs

Encouraging signs of changes in the sales trend in early promotion markets with August in-market sales returning to growth in Spain and Germany and improvements in other markets including France and Italy

The development of the new device by Tolmar is progressing, regulatory filing now expected in Q1 2022

as of September 30th

  • On track to deliver just over €80 million revenue for FY 2021

Countries directly promoting Eligard®

Countries indirectly promoting Eligard® by our partners

3

* Recordati books net margin as Revenue until distribution transfer from Astellas in 2021

Signifor® & Signifor LAR® sales growth continues in Q3 2021 Isturisa® launch on track in US, EU and JP

Signifor® and Signifor® LAR commercialization on track

  • YTD Q3 2021 reported Net Revenue of ~€58.5 million
  • Growth of in-market sales at constant exchange rate estimated to be around 10% vs 2020*
  • Continued new patient acquisition in all Regions across all approved indications
  • Transfer of Marketing Authorization almost finalized in wave 2 markets

Isturisa® launch and new patient acquisition progressing as planned

  • Isturisa® YTD Q3 2021 Net Revenue ~€32 million
  • Robust patient uptake in US, France and other EU markets
  • Reimbursement price agreed in Germany in line with expectation, discussion ongoing in other EU markets
  • Launched in Japan on June 30th, 2021. Performing according to plan
  • Strong support from top KOLs and patient organizations continues
  • Recordati books only margins on sales of Signifor® and Signifor LAR® until transfer of market authorizations and distribution from Novartis; in market

4 sales performance estimated through net margin gross up for like for like comparison

Main products sales

(million Euro)

9M 2021

9M 2020

Change %

Zanidip® (lercanidipine)

107.2

106.1

1.0

Seloken®/Seloken® ZOK/Logimax®

73.0

77.7

(6.1)

(metoprolol/metoprolol+felodipine)

Eligard®(1)

59.4

-

n.m.

Urorec® (silodosin)

45.3

58.5

(22.6)

Livazo® (pitavastatin)

31.8

42.5

(25.0)

Zanipress® (lercanidipine+enalapril)

31.3

38.2

(18.1)

Other corporate products (2)

198.1

198.7

(0.3)

Drugs for rare diseases

279.4

232.4

20.2

of which Endo franchise(3)

90.5

53.8

68.2

(1) Eligard® net revenue includes margins booked as net revenue until transfer of market authorizations and distribution

(2) Includes the OTC corporate products for an amount of € 79.3 million in 2021 and € 78.4 million in 2020

5

(3) Endo franchise net revenue 2020 includes margins on sales of Signifor® and Signifor® LAR until transfer of market authorizations

Questo è un estratto del contenuto originale. Per continuare a leggere, accedi al documento originale.

Disclaimer

Recordati S.p.A. published this content on 28 October 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 28 October 2021 13:32:05 UTC.


ę Publicnow 2021
All news about RECORDATI
01/12ITA Airways seeks an ally to put 'money on the table'
RE
2021Eton Pharmaceuticals, ANI Pharmaceuticals Launch Carglumic Acid Tablets for Hyperammone..
MT
2021RECORDATI : Kim stratton co-opted to the board of directors as a non-executive and non-ind..
PU
2021RECORDATI : Presentazione EUSA Pharma Acquisition
PU
2021RECORDATI : EUSA Pharma Acquisition
PU
2021Recordati To Acquire EUSA Pharma In $847 Million Deal
MT
2021Recordati to buy EUSA Pharma for $847 million to boost rare disease offering
RE
2021RECORDATI : TO ACQUIRE EUSA PHARMA (UK) Ltd, A GLOBAL SPECIALTY PHARMACEUTICAL COMPANY FOC..
PU
2021Recordati Industria Chimica e Farmaceutica S.p.A. agreed to acquire Eusa Pharma (Uk) Li..
CI
2021Recordati's CEO Takes Over Chair Role; New CEO Appointed
MT
More news
Analyst Recommendations on RECORDATI
More recommendations
Financials
Sales 2021 1 579 M 1 792 M 1 792 M
Net income 2021 407 M 462 M 462 M
Net Debt 2021 858 M 973 M 973 M
P/E ratio 2021 26,6x
Yield 2021 2,18%
Capitalization 10 564 M 11 989 M 11 987 M
EV / Sales 2021 7,23x
EV / Sales 2022 6,72x
Nbr of Employees 4 446
Free-Float -
Chart RECORDATI
Duration : Period :
Recordati Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECORDATI
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 11
Last Close Price 51,20 €
Average target price 50,54 €
Spread / Average Target -1,30%
EPS Revisions
Managers and Directors
Robert Koremans Chief Executive Officer
Luigi Felice la Corte Group Chief Financial Officer
Andrea Recordati Chairman
Raffaele Sabia Senior VP-Pharmaceutical Research & Development
Giovanni Minora Head-Group Audit & Compliance
Sector and Competitors
1st jan.Capi. (M$)
RECORDATI-7.58%12 209
JOHNSON & JOHNSON-2.32%439 907
ROCHE HOLDING AG-3.75%322 066
PFIZER, INC.-8.37%303 712
ABBVIE INC.1.02%241 811
ELI LILLY AND COMPANY-10.55%223 992